Title
Cancer-related pain management in clinical oncology.

Permalink
https://escholarship.org/uc/item/54n3r8ft

Journal
The Journal of community and supportive oncology, 13(10)

ISSN
2330-7749

Authors
Cipta, AM
Pietras, Cj
Weiss, TE
et al.

Publication Date
2015-10-01

DOI
10.12788/jcso.0173

Peer reviewed
Cancer-related pain management in clinical oncology

Andre M Cipta, MD, Christopher J Pietras, MD, Timothy E Weiss, MD, and Thomas B Strouse, MD

‘Department of Geriatrics and Palliative Medicine, Kaiser Permanente, West Los Angeles, California; and Hospice and Palliative Medicine, Department of Medicine, and Maddie Katz Professor of Psychiatry and Palliative Care Research and Education, David Geffen School of Medicine, University of California, Los Angeles

Uncontrolled pain is one of the most feared and debilitating symptoms among cancer patients, and many suffer unnecessarily from suboptimal pain control. Cancer-related pain is often multidimensional and can affect all aspects of a patient’s life. Hence, achieving adequate pain relief among cancer patients involves a proper assessment of psychosocial, spiritual, and physical pain issues, matched with an individualized treatment plan involving pharmacologic, nonpharmacologic, and procedural therapies when appropriate. Providing effective pain relief can help ease the overall burden of disease among oncology patients while helping them tolerate cancer-directed therapies and achieve the most optimal quality of life throughout all phases of the disease continuum. In this review, the authors will discuss the syndromes, assessment of, and treatment for cancer-related pain in the outpatient setting.

Clinical oncologists know that pain is prevalent among cancer patients and can present during any phase of illness. A meta-analysis described pain in 59% of patients in active treatment, 33% of survivors after treatment, and 64% of those with metastatic, advanced, or terminal disease. Pain is not only one of the most common cancer-related symptoms but among the most feared. Suboptimal pain management can lead to severe and unnecessary physical suffering, hindered relationships, and an overall decrease in patient quality of life.

Despite recognition of its importance, pain management for patients with cancer is not always adequate. In a prospective study published in 2012 that assessed more than 3,000 outpatients, 33% of cancer patients reporting pain were found to be receiving inadequate analgesia, and 23% of patients with severe pain and 27% of those with moderate pain were not receiving any analgesia. A review of 26 relevant studies conducted in 2008 suggested that 43% of cancer patients had pain that was undertreated. Cancer-related pain is often multifactorial and may involve the malignancy itself, oncologic treatments, as well as psychosocial and spiritual distress. One study found that 60%-65% of cancer pain is related to direct tumor involvement, 20%-25% is related to cancer treatment, and 10%-15% is unrelated to the actual cancer.

Malignancies can directly involve the bone, nerves, or viscera and can also produce an inflammatory response that can lead to worsening pain. Pain mechanisms can be categorized as neuropathic or nociceptive; nociceptive pain is often further categorized into somatic or visceral subtypes. Somatic pain results from injury to the skin, subcutaneous tissue, bone, muscle, blood vessels, and connective tissue; it is often described as localized, con-
Visceral pain arises from damage to organs and the lining of body cavities, and can be described as poorly localized, cramping, and deep. Neuropathic pain arises from injury to nerve tissue, and is often described as burning, shooting, and electrical. Frequently neuropathic pain persists in the absence of ongoing neural tissue injury. Allodynia (pain response to a normally innocuous stimulus) and hyperalgesia (increased pain response to a normally painful stimulus) can also occur, and severe nerve damage can result in paresthesia, numbness, weakness, and muscle wasting.

Pain is one of the most common symptoms related to cancer therapy (Table 1). About 20% of chronic cancer pain problems are related to adverse consequences of chemotherapy, surgery, and radiation. Among breast cancer survivors, 42% of patients have chronic pain. Chemotherapy agents, including taxanes, vinca alkaloids, platinum-based compounds, epothilones, bortezomib, thalidomide, and lenalidomide, can lead to both acute and chronic neuropathic pain. The incidence of chemotherapy-induced peripheral neuropathy (CIPN) ranges from 30%-40% of patients receiving chemotherapy. CIPN predominantly affects the peripheral nervous system and presents as a dose-dependent, sensory polyneuropathy that often begins acutely in the hands and feet.

Surgical interventions, such as thoracotomies or mastectomies, can also lead to pain syndromes. Chronic pain was noted in 20% of women after mastectomy or lumpectomy with axillary node dissection. This is thought to be due to intercostobrachial nerve trauma. Similarly, patients who have undergone thoracotomies or port insertions for intravenous access may develop postthoracotomy syndrome, presenting as numbness, tenderness, and burning sensations over the surgical site, likely from injury to the intercostal nerves. Radiation therapy can lead to plexopathies, enteritis, and proctitis.

Psychosocial distress exists among cancer patients and has a reciprocal relationship with physical pain. Studies of terminally ill cancer patients found that one-fourth experienced adjustment disorders and/or major depression, and terminally ill cancer patients who were depressed were 4 times more likely to have a high desire for hastened death than were nondepressed patients. Cancer pain has also been identified as one of the largest contributors to emotional distress among cancer patients. Conversely, psychosocial stress can exacerbate physical pain, as was elucidated by a meta-analysis of randomized controlled studies on adult cancer patients during 1966-2010 that found positive effects of psychosocial interventions on pain severity.

Similarly, spiritual interventions can be important for some patients. Spirituality can be defined as the way in which people seek and express meaning and purpose in life, and involves an individual’s interconnectedness with oneself, others, and that which one considers significant and sacred. Hence, it is no surprise that spiritual distress exists among cancer patients as their illness can affect their values, hopes, fears, and relationships. As their disease progresses, cancer patients may find themselves wrestling with existential questions related to the purpose and meaning of life, death, sickness, and suffering. Research on end-stage cancer patients demonstrated a significant correlation between the will to live and existential, psychological, social, and physical sources of distress.

Oncologic pain emergencies may also arise. In particular, malignant epidural spinal cord compression is a medical emergency that affects about 5%-10% of adult solid tumor patients. It can lead to permanent neurologic impairment and paraplegia if it is not diagnosed early and treated.

<table>
<thead>
<tr>
<th>TABLE 1 Pain syndromes associated with oncologic therapeutic interventions</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention</td>
<td>Pain syndrome</td>
</tr>
<tr>
<td>Chemotherapy</td>
<td>Mucositis, corticosteroid-induced perineal discomfort, peripheral neuropathy, chemotherapy-related headache, taxol-induced arthralgia and myalgia, 5-fluouracil-induced angina chest pain, palmar-planar erythrodysthesia syndrome, chemotherapy-induced digital ischemia, avascular necrosis of femoral or humeral head, plexopathies, Raynaud’s phenomenon</td>
</tr>
<tr>
<td>Hormonal therapy</td>
<td>Leutensing hormone-releasing factor tumor flare in prostate cancer, hormone-induced pain flare in breast cancer, aromatase inhibitor-induced arthralgias</td>
</tr>
<tr>
<td>Radiotherapy</td>
<td>Oropharyngeal mucositis, radiation enteritis, proctocolitis and cystitis, plexopathies, radation myelopathy, radiopharmaceutical-induced bone flare, lymphedema pain, burning perineum syndrome, post-prostate brachytherapy pelvic pain, osteoradionecrosis</td>
</tr>
<tr>
<td>Post-surgical</td>
<td>Breast surgery pain syndromes, postradical neck dissection pain, postthoracotomy pain, postthoracotomy/mastectomy frozen shoulder, postamputation phantom pain syndrome, stump pain, postsurgical pelvic floor myalgia</td>
</tr>
<tr>
<td>Chemotherapy infusion techniques</td>
<td>Intravenous infusion pain, intra peritoneal chemotherapy pain</td>
</tr>
<tr>
<td>Analgesic techniques</td>
<td>Local anesthetic infiltration pain, opioid injection pain, opioid headache, spinal opioid hyperalgesia syndrome, epidural injection pain</td>
</tr>
</tbody>
</table>
appropriately. The diagnosis of malignant spinal cord compression can be missed because it does not typically present as a unique pain syndrome and may not have abnormal neurologic findings on history or physical exam. Early identification is vital because neurologic symptoms may be irreversible by the time symptoms arise, whereas patients who are treated while still ambulatory have a 90% chance of remaining ambulatory.

In addition to clinical awareness, knowing when to obtain imaging studies and which imaging study to order are essential. A cancer patient with back pain and abnormal plain films of the spine has a 70% chance of having an epidural metastasis; however, as many as 5% of cancer patients with a normal bone scan will have metastatic bony disease on MRI. In cancer patients, the symptom of back pain should alert clinicians to evaluate for bone metastasis and consider obtaining appropriate imaging studies.

**Assessment**

The pain assessment is a vital component of cancer pain management. A study that surveyed physicians found that 76% of physicians identified poor pain assessment as the single most important barrier to adequate pain management. An effective cancer pain assessment identifies underlying pain syndromes and mechanisms to develop the most effective treatment plan for pain control. An effective pain assessment is predicated on a trusting physician-patient relationship and includes a detailed medical and pain history, physical exam, psychosocial and spiritual evaluation, and screen for substance abuse.

Obtaining a detailed pain history involves identifying pain characteristics, such as pain intensity, quality, location, radiation, and alleviating and aggravating factors. It is important to note temporal features (i.e., acute, subacute, chronic), whether the pain is constant or episodic, and to establish a chronicologic timeline of symptom presentation in the context of the underlying disease trajectory because cancer pain can be caused by either the malignancy itself or its treatments. Review of diagnostic studies can also be useful in identifying particular syndromes, and an appropriate physical exam can help identify underlying pain mechanisms. For example, decreased sensation, allodynia, hyperalgesia, or weakness may suggest neuropathic pain, whereas point tenderness over a bone may suggest malignant bony involvement. Current and previous pain management regimens should be evaluated, noting compliance, effectiveness, and adverse effects of therapies.

Validated self-reporting scales are useful tools to help characterize, rate, and monitor a patient’s pain and response to therapy. The Agency for Healthcare Research and Quality, the American Pain Society, and the World Health Organization all identify assessment of pain through patient reporting as the most important factor in determining treatment. Their guidelines recommend using pain-rating scales in all patients who commence or change treatments in order to assess pain severity and relief. The most frequently used validated scales include the visual analog scale (VAS), the verbal rating scale (VRS), and the numerical rating scale (NRS). In cases in which communication or cognitive ability are impaired, physical and behavioral signs of discomfort (i.e., facial grimacing, vocalizations, changes in interpersonal interactions, body movements) can be used to assess the presence of pain; however, these methods may be limited in their assessment of pain intensity. In these cases, the Pain Assessment in Advanced Dementia (PAINAD) scale, and for children, the Wong-Baker Faces Pain Rating Scale, can be useful. It is also important to assess the way in which pain affects various aspects of a person’s life, including activities of daily living, appetite, sleep, vitality, and relationships. More comprehensive tools that evaluate these functional dimensions include the Brief Pain Inventory, the Memorial Symptom Assessment Scale, and the Edmonton Symptom Assessment Scale.

Given the reciprocal relationship between psycho-spiritual distress and physical pain, it is important for clinicians to perform an appropriate psychiatric and spiritual evaluation. While a thorough history and physical examination is the gold standard for the assessment of psycho-spiritual problems, an oncologist in a busy clinic setting might instead rely on staff-administered screening tools to provide an effective and time-efficient method to evaluate psycho-spiritual issues and identify patients who may benefit from further discussions, including a referral to mental health and spiritual care specialists. Useful clinical tools to assess physical and psycho-spiritual distress include the National Comprehensive Cancer Network Distress Thermometer for Patients and the Alberta Health Services Screening for Distress tool. Spiritual health may be further evaluated using the FICA (Faith/Beliefs, Importance, Community, Address in care or action) and similar clinical tools.

Delirium, depression, and anxiety are among the most common psychiatric problems that afflict cancer patients and are interconnected with pain management. The Confusion Assessment Method is a brief screening tool for delirium that has been validated in many patient populations, including patients with advanced illnesses. More detailed diagnostic tools, such as the Delirium Rating Scale Revised-98 and the Memorial Delirium Assessment Scale, can be used to confirm the diagnosis of delirium and monitor changes over time. It is important to be attentive to the various delirium subtypes (hypoactive, hyperactive or mixed) and identify any reversible causes, such as dehydration, electrolyte abnormalities, infection, pain, and medications (i.e., opioids, benzodiazepines, anticholinergics, steroids).
Depression can present as changes in mood, vitality, sleep, appetite, and weight, and is often linked to disease progression and diminished quality of life. Depression screening tests that have demonstrated benefit in oncology patients include the Patient Health Questionnaire, the Zung Depression Scale, and the Beck Depression Inventory. The Hospital Anxiety and Depression Scale is an efficient and commonly used screening tool for anxiety among cancer patients and can also help screen for depression. A medication review is important as depression can be induced by certain medications, including corticosteroids, interferon, and drugs that block estrogen receptors (ie, tamoxifen).

Screening for substance abuse in patients and their families is another important component of the pain assessment. In the context of a serious public health problem in the United States in the last 15 years—a true epidemic of prescription opioid abuse and diversion—some experts are advocating for universal precautions (eg, substance abuse risk/screening) for all patients who are being prescribed opioids. Although many cancer pain management and palliative care clinicians disagree with this strategy for their patients, oncologists should at least be aware that some state medical boards and other agencies have taken fairly strong stances on this issue. Optimal evaluation and management of substance abuse involves a multidisciplinary team that includes social workers, psychologists, psychiatrists, chaplains, and mental health professionals who specialize in substance abuse. Screening tools, including the Screener and Opioid Assessment for Patients with Pain (SOAPP), the Opioid Risk Tool (ORT), and the Diagnosis, Intractability, Risk, and Efficacy (DIRE) inventory, can assist in evaluating the likelihood of inappropriate drug use in chronic pain patients. A comparative study on common screening methods for predicting aberrant drug-related behavior in chronic pain patients who received opioids demonstrated the highest sensitivity for the clinical interview and the SOAPP, followed by the ORT and the DIRE. A treatment contract can be useful in establishing clear expectations for the physician and patient and in outlining the consequences of aberrant medication use. Such a contract may include spot urine toxicology screens, expectations for follow-up visits, management of medication supply, and requirement of joint management with a substance abuse specialist.

**Treatment**

The goal of cancer-related pain treatment is to enhance patient quality of life by providing sustained and effective pain relief with tolerable side effects. Pain treatments can be categorized into pharmacologic, nonpharmacologic, and interventional therapies. Pharmacologic therapies can be further divided into opioids, nonopioids, and adjuvants. There exist various types of opioids, including opioid receptor agonists, partial agonists, and mixed agonists-antagonists, with the agonist agents being the most effective and commonly used for analgesia. Of the various opioid receptors, the mu receptor is the most clinically relevant in terms of analgesia and related adverse effects.

Opioid selection should be individualized. Numerous splice variants of the mu receptor gene are thought to lead to clinical variability in opioid efficacy and adverse effects. When selecting an opioid, clinicians should consider patients’ past experiences with opioids, including both analgesic benefit and tolerability. For opioid naïve patients, starting with one of the pure mu receptor agonists while monitoring for both clinical benefit and adverse effects would be a reasonable approach. Indeed, the most appropriate opioid for a patient is the one that works best for them. Opioids have multiple routes of administration and are produced in long- and short-acting formulations (Tables 2 and 3). Because opioids alter pain perception and signal transmission, they can have an analgesic effect in different types of pain syndromes, regardless of the under-

<table>
<thead>
<tr>
<th>TABLE 2 Immediate-release oral opioids</th>
<th>Opioid</th>
<th>Dose, mg</th>
<th>Routes</th>
<th>Interval, h</th>
<th>Onset, min</th>
<th>Peak, min</th>
<th>Half-life, h</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morphine sulfate</td>
<td>15, 30</td>
<td>PO, IV, SL, SC, PR</td>
<td>q3-6</td>
<td>15-60</td>
<td>60-90</td>
<td>2-4</td>
<td></td>
</tr>
<tr>
<td>Hydromorphone</td>
<td>2, 4, 8</td>
<td>PO, IV, SL, SC, PR</td>
<td>q3-4</td>
<td>15-30</td>
<td>30-90</td>
<td>2-3</td>
<td></td>
</tr>
<tr>
<td>Oxycodone</td>
<td>5, 10, 15, 20, 30</td>
<td>PO, SL, PR</td>
<td>q3-4</td>
<td>15-30</td>
<td>60-90</td>
<td>2-3</td>
<td></td>
</tr>
<tr>
<td>Methadone</td>
<td>5, 10, 40</td>
<td>PO, IV, SL, SC, PR</td>
<td>q4-12</td>
<td>30-60</td>
<td>30-90</td>
<td>12-150</td>
<td></td>
</tr>
<tr>
<td>Hydrocodone/acetaminophen</td>
<td>2.5/325, 5/325, 7.5/325, 10/325 PO</td>
<td>q4-6</td>
<td>30-60</td>
<td>60-90</td>
<td>4.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Codeine</td>
<td>15, 30, 60</td>
<td>PO</td>
<td>q4-6</td>
<td>15-30</td>
<td>60-90</td>
<td>2-4</td>
<td></td>
</tr>
<tr>
<td>Tramadol</td>
<td>50</td>
<td>PO</td>
<td>q4-6</td>
<td>60</td>
<td>120</td>
<td>6-8</td>
<td></td>
</tr>
</tbody>
</table>

IV, intravenously; SC, subcutaneous; SL, sublingual; PO, by mouth; PR, by rectum

*aDilute methadone when using subcutaneous route secondary to local irritation.*
lying pathophysiology. Most opioids have similar initial adverse effects, such as sedation and nausea, which typically resolve after a few days. Other, more serious adverse effects that clinicians and patients should be aware of include confusion, nightmares, hallucinations, urinary retention, myoclonus, dizziness, and dysphoria. In general, opioids should be used cautiously in patients who are in acute pain with impaired ventilation, bronchial asthma, or raised intracranial pressure; however, the same caveats should not typically limit dose titrations in chronic cancer pain management. In the case in which an opioid is ineffective despite increased doses or its side effects become unmanageable, it would be appropriate to rotate to a different opioid.

Commonly used pure mu receptor agonists include morphine, hydromorphone, oxycodone, hydrocodone, fentanyl, and methadone. Although morphine was traditionally considered the gold standard for opioids, there does not seem to be a demonstrable difference in effectiveness among the different opioids. Hydromorphone is a derivative of morphine that is about 5-10 times more potent than morphine. Oxycodone is a synthetic opioid that is slightly more potent than oral morphine and seems to have similar adverse effects to morphine and hydromorphone. Hydromorphone is found in combination products with acetaminophen and ibuprofen, and a liquid cough formulation exists in combination with homatropine. Fentanyl is a highly lipidsoluble opioid that has a long-acting transdermal formulation that provides an alternate route of administration in patients for whom ingestion of oral medications may be difficult or impossible. The absorption of transdermal fentanyl can be affected by edema, body temperature, and fat content. Although other opioids have active metabolites that can cause neurotoxicity in the setting of renal impairment, fentanyl and methadone are safer alternatives in patients with renal failure because they do not have active metabolites.

Long-acting opioids, or controlled-release opioids, can provide greater pain relief in patients whose pain is not optimized with short-acting opioid formulations. Controlled-release opioids should not be used in opioid naive patients, and clinicians and patients should be aware of the associated risks of opioid addiction and misuse, which can lead to overdose and death. There are various controlled-release opioid formulations available (Table 3), including hydromorphone, oxycodone, and morphine. In patients who have difficulty swallowing, 2 morphine formulations, Avinza and Kadian, would be of benefit as they can be sprinkled, whereas other controlled-release opioids should not be crushed. Another controlled-release opioid, oxymorphone (Opana ER), should be taken 1 hour before or 2 hours after meals, because its peak varies with food intake.

Methadone acts as an opioid receptor agonist and an NMDA (N-methyl-d-aspartate) receptor antagonist, and also blocks the reuptake of serotonin and norepinephrine. Given its various mechanisms of action, methadone can be effective in multifaceted pain syndromes involving both somatic and neuropathic pain, although there are conflicting results in neuropathic pain studies. Given methadone’s variable and long half-life, clinicians should be watchful for adverse events as a result of drug accumulation. Methadone’s pharmacokinetics can be especially variable in cancer patients because methadone binds avidly to alpha1-glycoproteins, the levels of which are increased in cancer patients, which can lead to a decrease in unbound methadone and a delayed onset of effect. Because methadone is metabolized primarily by CYP3A4, clinicians should be aware of other medications that may inhibit or induce the CYP3A4 enzyme. Methadone can prolong the QTc interval, so QTc monitoring may be warranted in appropriate settings. Recent guidelines suggest that methadone should be prescribed only by clinicians who are familiar with its use, such as palliative medicine, pain, and addiction medicine specialists.

There are other weaker agents, such as codeine and tramadol. Codeine is an opioid alkaloid whose action is dependent on its metabolism to the active form, morphine. Because of codeine’s genetic variability in its rate of metabolism, its use should be individualized. Tramadol is a synthetic analog of codeine that has shown efficacy in neuropathic pain, but has no anti-inflammatory activity. It can increase the risk of seizures and serotonin syndrome because it is also a monoamine reuptake inhibitor. Unlike the stronger opioids, there is a “ceiling effect” for these medications, that is, above a certain threshold dose, there is no additional analgesic effect but there is still the potential for adverse effects.
Commonly used nonopioid medications include nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen. NSAIDs can be quite effective in controlling pain caused by inflammatory processes and/or bone metastasis but can have potential adverse effects, such as gastrointestinal bleeding, platelet dysfunction, and renal failure. Patients with a history of gastritis or gastrointestinal bleeds should either be on a combination of a nonselective NSAID with a proton pump inhibitor or switched to a selective cyclooxygenase (COX2) inhibitor. It is important to note that COX2 inhibitors do not protect against renal failure and may present an increased risk of thrombotic cardiovascular events. Acetaminophen can also be an effective analgesic for cancer pain, but should be used cautiously in patients with hepatic impairment.

Adjuvant analgesics are medications that are not primarily indicated for pain management but can be an effective analgesic in various pain syndromes. Commonly used adjuvants that are used to treat neuropathic pain include anticonvulsants, antidepressants, corticosteroids, ketamine, and cannabinoids. Gabapentin is the most commonly used anticonvulsant for neuropathic pain and can have an added analgesic effect when used in combination with tricyclic antidepressants such as nortriptyline. Its main side effects are somnolence and dizziness. Whereas gabapentin's bioavailability decreases at higher doses (60%-80% percent bioavailability at 100 mg every 8 hours vs 27% at 1600 mg every 8 hours), the gabapentin analog pregabalin is linearly absorbed in all doses. Hence, pregabalin may be a more effective alternative to gabapentin in patients requiring higher doses of the medication. Serotonin norepinephrine reuptake inhibitors, such as venlafaxine and duloxetine, are recommended along with gabapentin and pregabalin as first-line treatments for diabetic neuropathic pain.

Tricyclic antidepressants can be useful for neuropathic pain with the added benefit of improving mood and sleep; however, their use may be limited in the elderly because of its anticholinergic effects and it should also be avoided in patients with glaucoma and those who are suicidal. Corticosteroids reduce inflammation, inhibit prostaglandin production, and reduce neuronal excitability, which makes it particularly useful in metastatic bone pain and neuropathic pain caused by spinal cord or nerve plexus compression. Corticosteroids also provide the additional benefits of improved appetite, malaise, and nausea. Transdermal lidocaine has been approved by the US Food and Drug Administration for postherpetic neuralgia, but may also be effective in other neuropathic pain conditions, including postmastectomy pain syndrome and diabetic neuropathy. Ketamine is a pure NMDA antagonist that has been shown to improve neuropathic cancer pain; potential adverse effects include sedation, delirium, and hallucinations, especially at higher doses. Although data in cancer pain is limited, cannabinoids have been shown to be of benefit in neuropathic pain in HIV-positive patients.

In addition to NSAIDs and corticosteroids, bone-metabolism modifying agents can help relieve cancer-related bone pain. Bisphosphonates inhibit osteoclast activity and can provide relief from metastatic bone pain. The American Society of Clinical Oncology recommends using pamidronate or zoledronic acid; however, these medications should be avoided in the setting of renal failure, and patients should be aware that both medications can initially worsen the pain due to an acute phase reaction. The RANK-L inhibitor denosumab prevents bone resorption and osteoclast maturation and activation. Denosumab can improve bone pain, is not renal toxic, and causes fewer episodes of acute phase reactions compared with zolendronic acid. Calcitonin reduces bone resorption, and although the evidence is scarce for its effectiveness in treating cancer-related bone pain, it is generally well tolerated.

Various nonpharmacologic modalities can also help treat cancer-related pain. There are many studies supporting the use of cognitive and behavioral therapy (CBT) for chronic pain management; however, results are mixed for the effectiveness of CBT in cancer-related pain. Acupuncture, therapeutic massage and exercise can also be effective in managing all types of cancer-related pain. Transcutaneous electrical nerve stimulation, topical heat, and ice therapy are other topical therapies that can provide pain relief with few adverse effects. Mind-body interventions such as biofeedback, diversion of attention, relaxation breathing, meditation, and music and art therapy can all be useful in managing cancer pain.

Interventional therapies are also available to treat cancer-related pain, and are particularly effective in severe cases that are refractory to systemic analgesics and cases in which intolerable side effects limit medication use. Celiac plexus blocks can provide long-lasting benefit for 70%-90% of patients with pancreatic and other abdominal malignancies, and hypogastric plexus blocks can be effective in chronic cancer-related pelvic pain. Intrathecal pumps deliver opioids directly into the subarachnoid space, achieving equianalgesic effect at much lower doses than do systemic administrations, thereby decreasing the risk of opioid dose-related adverse effects.

External beam radiation can be an effective treatment option for localized metastatic bone pain. It provides pain relief in 50% and 75% of patients at 2 and 4 weeks, respectively, after treatment, and for most patients, pain relief lasts for 3 months. Single fraction radiation is recommended over multiple-fraction regimens for the treatment of metastatic bone pain. There is no difference in the duration of or time to pain relief between single large fraction radiation and conventional radiation treatments involving mul-
multiple fractions; however, there is a higher retreatment rate in single fraction radiation.\textsuperscript{78} Patients should also be aware of a possible transient increase in pain at the treatment site, which may be decreased with NSAIDs or corticosteroids.\textsuperscript{79}

In cases in which optimal pain relief is not achieved despite medication and interventional therapies, surgical procedures, such as cordotomy and myelotomy, may be of benefit. Cordotomy is indicated for unilateral medically intractable cancer pain below the level of C5 and can provide immediate pain relief in over 90\% of patients; although, the analgesic effect decreases to 40\% after 1 year.\textsuperscript{80} Vertebroplasty can be effective in vertebral compressions from bone metastasis,\textsuperscript{81} and kyphoplasty has been demonstrated to be safe and effective in bone pain associated with multiple myeloma.\textsuperscript{82} Case reports have suggested a high success rate in pain control for patients with malignant compression fractures and indicate pain relief within 48 hours after vertebroplasty.\textsuperscript{83}

There are a number of barriers to effective cancer-related pain management, including physician-related barriers, patient-related barriers and society and tradition-related barriers.\textsuperscript{84} A review of empirical research on these barriers in the literature identified the most significant patient-related barriers were patient reluctance to report pain and adhere to treatment recommendations.\textsuperscript{85} The most prominent physician-related barriers were insufficient physicians’ knowledge about cancer pain management, inadequate patterns of pain assessment, and inadequate opioid prescription. A large multicenter study that surveyed physicians identified a number of critical barriers to effective cancer pain management (Table 4) with 76\% of physicians designating poor pain assessment as the single most important barrier to adequate pain management.\textsuperscript{86}

<table>
<thead>
<tr>
<th>Table 4 Barriers to management of cancer pain\textsuperscript{87}</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inadequate pain assessment</strong></td>
</tr>
<tr>
<td><strong>Patient reluctance to report pain</strong></td>
</tr>
<tr>
<td><strong>Patient reluctance to take opioids</strong></td>
</tr>
<tr>
<td><strong>Physician reluctance to prescribe opioids</strong></td>
</tr>
<tr>
<td><strong>Inadequate staff knowledge about pain management</strong></td>
</tr>
<tr>
<td><strong>Nursing staff reluctance to give opioids</strong></td>
</tr>
<tr>
<td><strong>Excessive state regulation of analgesics</strong></td>
</tr>
<tr>
<td><strong>Lack of access to professional methods</strong></td>
</tr>
<tr>
<td><strong>Lack of psychological support services</strong></td>
</tr>
<tr>
<td><strong>Lack of equipment</strong></td>
</tr>
<tr>
<td><strong>Lack of neurodestructive procedures</strong></td>
</tr>
<tr>
<td><strong>Lack of access to wide range of analgesics</strong></td>
</tr>
</tbody>
</table>

\textsuperscript{Adapted from van Roenn et al\textsuperscript{88}}

Summary

Uncontrolled pain is one of the most feared and debilitating symptoms among cancer patients, and many suffer unnecessarily from suboptimal pain control. Pain can affect all aspects of a patient’s life, and each individual has a unique experience in how they manage, cope and respond to their pain and related treatments. Hence, achieving adequate pain relief involves a proper assessment of psychosocial, spiritual and physical pain issues, matched with an individualized treatment plan involving pharmacologic, nonpharmacologic and procedural therapies when appropriate. Indeed, the optimal context in which pain management occurs is within a multidisciplinary health care team, involving oncologists, pain management and palliative medicine specialists, nurses, chaplains, social workers, physical and occupational therapists, complementary and alternative medicine specialists, psychiatrists, psychologists, surgeons, and radiologists. Providing adequate pain relief can help ease the overall burden of disease among oncology patients while helping them tolerate cancer-directed therapies and achieve the most optimal quality of life throughout all phases of the disease process.

References

12. Massie MJ, Gagnon P, Holland JC. Depression and suicide in pa-